- •Incident ASCVD rates were higher in adults with diabetes/prediabetes than without.
- •Whites with diabetes/prediabetes and elevated Lp(a) had even greater ASCVD risk.
- •Adding Lp(a) to traditional risk factors improved ASCVD risk prediction.
- •Measuring Lp(a) may benefit ASCVD risk stratification in diabetes/prediabetes.
Background and aims
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.J. Am. Med. Assoc. 2009; 301: 2331-2339
- Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.J. Am. Med. Assoc. 2009; 302: 412-423
- Genetic variants associated with Lp(a) lipoprotein level and coronary disease.N. Engl. J. Med. 2009; 361: 2518-2528
- Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.N. Engl. J. Med. 2005; 353: 46-57
- Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study.Lancet. 2006; 368: 29-36
- 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J. Am. Coll. Cardiol. 2014; 63: 2889-2934
- Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.Eur. Heart J. 2017; 38: 2490-2498
- Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study.Circulation. 2012; 125: 241-249
- The Atherosclerosis Risk in Communities (ARIC) study: design and objectives.Am. J. Epidemiol. 1989; 129: 687-702
- Lipoprotein (a) measurements for clinical application.J. Lipid Res. 2016; 57: 526-537
- Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994.N. Engl. J. Med. 1998; 339: 861-867
US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease and colorectal cancer: preventive medication. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer. Accessed 19 March 2018.
- ESC/EAS guidelines for the management of dyslipidaemias.Eur. Heart J. 2016; 37 (2016): 2999-3058
- National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1--full report.J. Clin. Lipidol. 2015; 9: 129-169
- NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis.J. Am. Coll. Cardiol. 2018; 71: 177-192
- Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study.J. Am. Coll. Cardiol. 2014; 64: 851-860
- High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects.Arterioscler. Thromb. 1991; 11: 80-90
- Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage.Circulation. 2014; 130: 1374-1382
- Phenotypic characterization of genetically lowered human lipoprotein(a) levels.J. Am. Coll. Cardiol. 2016; 68: 2761-2772
- Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).Circulation. 2014; 129: 635-642
- Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study.Atherosclerosis. 2017; 256: 47-52
- Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.Atherosclerosis. 2009; 203: 371-376